Response to Letter to the Editor From Shaorong Yu and Jifeng Feng

We thank Drs. Yu and Feng for their letter responding to our article, which reports outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in the phase 2 PACIFIC-6 trial. 1 Garassino M.C. Mazieres J. Reck M. et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial. J Thorac Oncol. 2022; 17: 1415-1427 Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar Our article communicates the primary end point, the incidence of grade 3/4 adverse events possibly related to treatment within 6 months. Their letter mentions several perceived shortcomings of our article. Comment on “Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial”Journal of Thoracic OncologyVol. 19Issue 1PreviewBefore the approval of durvalumab, the frequently recommended treatment for unresectable stage III NSCLC was concurrent platinum-based chemoradiotherapy. Nevertheless, previous studies have revealed that such patients who receive concurrent chemoradiotherapy have poor median progression-free survival and overall survival, and a certain percentage of patients do not tolerate chemoradiotherapy.1,2 We read with interest a recent article in the Journal of Thoracic Oncology by Garassino et al.3 entitled “Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.” The authors highlighted that durvalumab has a safety profile similar to concurrent chemoradiotherapy in sequential chemoradiotherapy and an encouraging preliminary efficacy in frailer patients. Full-Text PDF